Ampio pharmaceuticals, inc. (AMPE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash flows from operating activities
Net (loss) income

-13,630

33,986

-51,891

-19,163

-33,713

-39,048

-24,528

-11,593

-

Unrealized loss on fair value of debt instruments

-

-

-

-

-

-

-

-

-5,585

Adjustments to reconcile net (loss) income to net cash used in operating activities
Loss from discontinued operations

-

-

-

0

-9,606

-7,743

-

-

-

Stock-based compensation, net

405

444

744

1,516

4,957

7,176

3,448

1,522

1,983

Warrant modification expense

-

-

74

36

422

0

-

-

-

Net loss

-

-

-

-

-

-

-

-

-18,359

Depreciation and amortization

1,272

1,281

1,214

1,214

824

340

-

62

42

Loss from disposal of fixed assets

0

-123

0

-

-

-

-

-

-

Write-off of advances to stockholder

-

-

25

0

0

-

-

-

-

Loss on disposal of fixed assets

-

-

-

-

-

-28

-

-

-

Depreciation, amortization and accretion

-

-

-

-

-

-

137

-

-

Amortization of prepaid research and development - related party (Note 9)

-

-

323

143

143

113

-

-

-

Issuance of common stock for services

80

60

60

60

30

30

88

100

3

Derivative loss (gain)

4,869

45,298

-36,218

-915

0

0

-516

205

-1,555

Loss on equity investment in Aytu BioSciences, Inc.

-

-

-

-1,043

0

0

-

-

-

Unrealized loss on trading security in Aytu BioScience, Inc.

-

-

-

-146

0

0

-

-

-

Changes in operating assets and liabilities
(Increase) decrease in prepaid expenses

-

-

-

-

-

-

-

121

-17

Decrease (increase) in related party accounts receivable and payable

-

-

-

-38

38

-205

-

-

-

Increase in prepaid expenses and other

1,271

179

-129

-80

-298

537

-32

-

-

Increase in prepaid research and development - related party (Note 10)

-

-

-

-

-

725

-

-

-

Increase (decrease) in accounts payable and accrued expenses

2,700

-2,495

2,076

-1,095

-1,143

951

-

-

-

Decrease in lease liability

-70

-61

-

-

-

-

-

-

-

Increase in related party payable

-

-

-

-

-

-

-

-

-78

Decrease in accounts payable

-

-

-

-

-

-

699

570

166

Increase in interest payable

-

-

-

-

-

-

-

-

-2

Decrease in deferred rent

-

-

50

41

31

-720

-

-

-

(Decrease) increase in deferred revenue

-

-

-

-

-

-

-50

-50

481

Increase (decrease) in accrued compensation

-

-

-332

480

744

-380

522

-

-

(Decrease) in accrued bonuses

-

-

-

-

-

-

-

-

-526

Net cash used in operating activities - continuing operations

-

-

-

-14,624

-17,900

-23,380

-19,133

-9,715

-

Net cash used in operating activities - discontinuing operations

-

-

-

0

-8,543

-7,359

-

-

-

Net cash used in operating activities

-15,383

-12,139

-11,407

-14,624

-26,444

-30,740

-

-

-9,131

Cash flows used in investing activities
Purchase of fixed assets

22

564

72

6

110

8,668

1,311

-

84

Investment in Aytu BioScience, Inc.

-

-

-

0

16,300

5,400

-

-

-

Related party interest

-

-

-

0

-120

120

-

-

-

Proceeds from sale of fixed assets

-

-

-

-

-

2

-

-

-

Purchase of patents

-

-

-

-

-

-

330

-

-

Deposits

-

-

-

-

-

-10

23

-

-

Deposits

-

-

-

-

-

-

-

-15

35

Net cash used in investing activities - continuing operations

-

-

-

-6

-16,289

-14,176

-1,665

15

-

Net cash used in investing activities - discontinuing operations

-

-

-

0

-1,786

-1

-

-

-

Net cash used in investing activities

-22

-564

-72

-6

-18,076

-14,178

-

-

-119

Cash flows from financing activities
Proceeds from sale of common stock in connection with the equity distribution agreement

142

0

-

-

-

-

-

-

-

Costs related to sale of common stock in connection with the equity distribution agreement

144

0

-

-

-

-

-

-

-

Proceeds from sale of common stock in connection with the public offering

12,000

8,000

-

-

-

-

-

-

-

Costs related to sale of common stock in connection with the public offering

1,243

844

-

-

-

-

-

-

-

Proceeds from related party notes payable and debentures

-

-

-

-

-

-

-

-

382

Gross proceeds from issuance of common stock

-

-

0

3,750

0

-

25,301

17,542

22,435

Costs related to sale of common stock related to the confidentially marketed public offering

-

-

0

338

0

-

297

1,559

2,797

Proceeds from warrant exercises

3,874

4,287

-

-

-

-

-

-

-

Costs related to warrant exercises

277

0

-

-

-

-

-

-

-

Proceeds from sale of common stock related to the registered direct offering

-

-

13,339

-

-

-

-

-

-

Costs related to sale of common stock related to the registered direct offering

-

-

1,351

-

-

-

-

-

-

Repayment of advances to shareholders

-

-

-

65

0

0

-

-

-

Proceeds from option and warrant exercises

-

-

2,806

0

28

-

-

-

-

Proceeds from option exercises

0

636

-

-

-

15

441

-

-

Repayment of advances to shareholders

-

-

-

-

-

-

-

36

22

Net cash provided by financing activities - continuing operations

-

-

-

3,528

28

63,409

29,425

16,020

-

Net cash provided by financing activities - discontinuing operations

-

-

-

0

21,129

5,520

-

-

-

Payment of related party notes

-

-

-

-

-

-

-

-

100

Net cash provided by financing activities

14,352

12,079

14,794

3,528

21,157

68,930

-

-

19,942

Net change in cash and cash equivalents

-1,053

-624

-

-

-

-

-

-

-

Net change in cash and cash equivalents

-

-

3,314

-11,103

-23,362

24,011

8,626

6,320

10,691

Cash and cash equivalents of continuing operations

-

-

-

4,894

15,998

50,159

-

-

-

Interest paid

-

-

-

-

-

-

-

-

8

Income taxes paid

-

-

-

-

-

-

-

-

82

Non-cash transactions:
Initial lease liability arising from the adoption of ASU 2016-02

1,704

0

-

-

-

-

-

-

-

Initial recognition of right-of-use asset arising from the adoption of ASU 2016-02

1,168

0

-

-

-

-

-

-

-

Issuance of Luoxis stock for patents

-

-

-

-

-

-

50

-

-

Common stock issued for acquisition of DMI BioSciences, Inc.

-

-

-

-

-

-

-

-

7,852

Conversion of debentures to common stock

-

-

-

-

-

-

-

-

9,424

Warrant compensation from Luoxis common stock offering costs

-

-

-

-

-

-

-

180

888

Merger liability - shares exchanged for options

-

-

-

-

-

-

-

-

574

Debenture warrant exercise fair value adjustment

-

-

-

-

-

-

901

20

629

Fixed asset purchases included in accounts payable

-

-

-

-

-

377

-

-

-

Distribution to stockholders

-

-

-

13,018

0

0

-

-

-

Warrant derivative liability in connection with the confidentially marketed public offering

-

-

0

4,127

0

0

-

-

-

Warrant derivative liability in connection with the registered direct offering

-

-

4,618

-

-

-

-

-

-

Warrant derivative liability in connection with the public offering

0

8,009

369

88

0

0

-

-

-

Placement agent warrant exercises, net

-

-

0

0

0

-

-

-

-